Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published May 2022 | Published
Journal Article

Identifying Common Molecular Mechanisms in Experimental and Human Acute Kidney Injury

  • 1. ROR icon University of Southern California

Abstract

Acute kidney injury (AKI) is a highly prevalent, heterogeneous syndrome, associated with increased short- and long-term mortality. A multitude of different factors cause AKI including ischemia, sepsis, nephrotoxic drugs, and urinary tract obstruction. Upon injury, the kidney initiates an intrinsic repair program that can result in adaptive repair with regeneration of damaged nephrons and functional recovery of epithelial activity, or maladaptive repair and persistence of damaged epithelial cells with a characteristic proinflammatory, profibrotic molecular signature. Maladaptive repair is linked to disease progression from AKI to chronic kidney disease. Despite extensive efforts, no therapeutic strategies provide consistent benefit to AKI patients. Since kidney biopsies are rarely performed in the acute injury phase in humans, most of our understanding of AKI pathophysiology is derived from preclinical AKI models. This raises the question of how well experimental models of AKI reflect the molecular and cellular mechanisms underlying human AKI? Here, we provide a brief overview of available AKI models, discuss their strengths and limitations, and consider important aspects of the AKI response in mice and humans, with a particular focus on the role of proximal tubule cells in adaptive and maladaptive repair.

Copyright and License

© 2022 Elsevier Inc. All rights reserved.

Acknowledgement

We apologize to all researchers whose work could not be discussed owing to space limitations. We thank Dr. Seth Ruffins and the Optical Imaging Facility of the University of Southern California Stem Cell Department for technical support.

Funding

Supported by the German Research Foundation postdoctoral scholarship GE 3179/ 1-1 (L.M.S.G.), and the work in Andrew P. McMahon's laboratory is supported by grants from the National Institutes of Health (UC2 DK126024-01R01 DK054364R01 DK121409, and R01 DK126925-01) to Andrew P. McMahon.

Conflict of Interest

Andrew P. McMahon serves as a scientific advisor to Novartis, TRESTLE Biotherapeutics, eGENESIS, and IVIVA Medical. The remaining author reports no conflict of interest.

Additional details

Created:
November 15, 2024
Modified:
November 15, 2024